Paper40495487
Auranofin, an antirheumatic drug, shows anticancer stem cell potential via suppression of the Stat3 signal.
Ko SY and 7 others. BMB Rep, 2025. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Auranofin, an antirheumatic drug, shows anticancer stem cell potential via suppression of the Stat3 signal. Papers, record 40495487. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40495487
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Auranofin, an antirheumatic drug, shows anticancer stem cell potential via suppression of the Stat3 signal.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antirheumatic Agents | Major topic |
| Auranofin | Major topic |
| Neoplastic Stem Cells | Major topic |
| STAT3 Transcription Factor | Major topic |
| Female | |
| Humans | |
| Antineoplastic Agents | |
| Apoptosis | |
| Breast Neoplasms | |
| Cell Line, Tumor | |
| Cell Movement | |
| Cell Proliferation | |
| Interleukin-8 | |
| MCF-7 Cells | |
| Signal Transduction |
Source PubMed
References40
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18277610 | Auranofin inhibits overproduction of pro-inflammatory cytokines, cyclooxygenase expression and PGE2 production in macrophages. | Arch Pharm Res | 2008 | https://conductscience.org/library/papers/18277610 | PubMed |
| 2 | 30827998 | Potential Anticancer Activity of Auranofin. | Chem Pharm Bull (Tokyo) | 2019 | https://conductscience.org/library/papers/30827998 | PubMed |
| 3 | 35201489 | The gold complex auranofin: new perspectives for cancer therapy. | Discov Oncol | 2021 | https://conductscience.org/library/papers/35201489 | PubMed |
| 4 | 32522692 | STAT3: A key signaling molecule for converting cold to hot tumors. | Cancer Lett | 2020 | https://conductscience.org/library/papers/32522692 | PubMed |
| 5 | 35078017 | Thioredoxin reductase: An emerging pharmacologic target for radiosensitization of cancer. | Transl Oncol | 2022 | https://conductscience.org/library/papers/35078017 | PubMed |
| 6 | 28664387 | Overview of Cancer Stem Cells and Stemness for Community Oncologists. | Target Oncol | 2017 | https://conductscience.org/library/papers/28664387 | PubMed |
| 7 | 19760641 | Cancer stem cells: cell culture, markers, and targets for new therapies. | J Cell Biochem | 2009 | https://conductscience.org/library/papers/19760641 | PubMed |
| 8 | 34905391 | Understanding breast cancer as a global health concern. | Br J Radiol | 2022 | https://conductscience.org/library/papers/34905391 | PubMed |
| 9 | 36831661 | Targeted Therapy and Mechanisms of Drug Resistance in Breast Cancer. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/36831661 | PubMed |
| 10 | 35096183 | Epithelial-to-Mesenchymal Transition Signaling Pathways Responsible for Breast Cancer Metastasis. | Cell Mol Bioeng | 2022 | https://conductscience.org/library/papers/35096183 | PubMed |
| 11 | 24032691 | Targeting IL-8 signalling to inhibit breast cancer stem cell activity. | Expert Opin Ther Targets | 2013 | https://conductscience.org/library/papers/24032691 | PubMed |
| 12 | 33327542 | Breast Cancer Stem Cells: Biomarkers, Identification and Isolation Methods, Regulating Mechanisms, Cellular Origin, and Beyond. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/33327542 | PubMed |
| 13 | 34731781 | Auranofin: Past to Present, and repurposing. | Int Immunopharmacol | 2021 | https://conductscience.org/library/papers/34731781 | PubMed |
| 14 | 24041156 | Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells. | Breast Cancer Res | 2013 | https://conductscience.org/library/papers/24041156 | PubMed |
| 15 | 36915147 | Paracrine secretion of IL8 by breast cancer stem cells promotes therapeutic resistance and metastasis of the bulk tumor cells. | Cell Commun Signal | 2023 | https://conductscience.org/library/papers/36915147 | PubMed |
| 16 | 33584277 | The Breast Cancer Stem Cells Traits and Drug Resistance. | Front Pharmacol | 2020 | https://conductscience.org/library/papers/33584277 | PubMed |
| 17 | 34445421 | Physalin A, 13,14-Seco-16, 24-Cyclo-Steroid, Inhibits Stemness of Breast Cancer Cells by Regulation of Hedgehog Signaling Pathway and Yes-Associated Protein 1 (YAP1). | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34445421 | PubMed |
| 18 | 36120232 | Evaluation of CD44+/CD24- and Aldehyde Dehydrogenase Enzyme Markers in Cancer Stem Cells as Prognostic Indicators for Triple-Negative Breast Cancer. | Cureus | 2022 | https://conductscience.org/library/papers/36120232 | PubMed |
| 19 | 36860815 | Mechanisms of drug resistance in breast cancer liver metastases: Dilemmas and opportunities. | Mol Ther Oncolytics | 2023 | https://conductscience.org/library/papers/36860815 | PubMed |
| 20 | 29874570 | JAK/STAT3-Regulated Fatty Acid β-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance. | Cell Metab | 2018 | https://conductscience.org/library/papers/29874570 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42209569 | Evaluation of cytotoxic and cellular effects of zinc nanoparticles from Saccharum officinarum (Jaggery) extract on breast cancer cells. | Sci Rep | 2026 | https://conductscience.org/library/papers/42209569 | PubMed |
| 42157933 | Nuclear Galectin-1 Drives Cancer Progression through O-GlcNAcylation-Dependent Regulation of SOX2. | Int J Biol Sci | 2026 | https://conductscience.org/library/papers/42157933 | PubMed |
| 40834985 | Combination nitazoxanide and auranofin treatment has synergistic anticancer activity in anaplastic thyroid cancer through enhanced activation of oxidative stress that leads to apoptosis. | Cancer Lett | 2025 | https://conductscience.org/library/papers/40834985 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CXCL8 | 3576 | PubTator's text mining | https://conductscience.org/library/genes/3576 | NCBI Gene |
| STAT3 | 6774 | PubTator's text mining | https://conductscience.org/library/genes/6774 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40495487
GET https://conductscience.org/api/papers/v1/40495487/references?page=2